Skip to main content

Advertisement

SpringerLink
Log in

JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

Inappropriate activation of JAK/STAT pathway occurs with high frequency in human cancers and is associated with cancer cell survival and proliferation. However, its role in oesophageal squamous cell carcinoma (ESCC) is unknown.

Methods

By immunohistochemistry, we analysed the expression of two components of this pathway, phosphorylated JAK-1 (pJAK-1) and phosphorylated STAT-3 (pSTAT-3), in 100 ESCC tumours and paired non-neoplastic oesophageal epithelia. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients.

Results

We found that pJAK-1 and pSTAT-3 expression was not detectable in normal oesophageal squamous cells. Primary ESCC with pJAK-1-positive and pSTAT-3-positive expression was detected in the cancer cell nests of 78 and 72 cases, respectively. In addition, the Pearson’s correlation coefficient between pJAK-1 and pSTAT-3 expression was 0.806 (p<0.001). Moreover, pJAK-1 and pSTAT-3 expression was correlated with N stage (lymph node metastasis, both p=0.01), pTNM stage (p=0.008 and 0.009, respectively) and metastatic status (both p=0.01). Furthermore, pJAK-1 and pSTAT-3 expression was associated with shorter overall survival (both p<0.001) and shorter disease-free survival (p=0.005 and 0.006, respectively). By multivariate analysis, TNM clinical classification (T, p<0.001; N, p=0.002; M, p=0.02), pJAK-1 (p=0.002) and pSTAT-3 (p=0.003) were independent prognosis predictors of ESCC.

Conclusion

These results provide convincing evidence for the first time that the JAK/STAT pathway may participate in the progress of ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jiang H, Gong M, Cui Y et al (2010) Upregulation of caspase-3 expression in esophageal cancer correlates with favorable prognosis: an immunohistochemical study from a high incidence area in northern China. Dis Esophagus 23:487–492

    Article  PubMed  CAS  Google Scholar 

  2. Wang WS, Zhong HJ, Xiao DW et al (2010) The expression of CFL1 and N-WASP in esophageal squamous cell carcinoma and its correlation with clinicopathological features. Dis Esophagus 23:512–521

    Article  PubMed  Google Scholar 

  3. Delektorskaya VV, Chemeris GY, Kononets PV et al (2009) Clinical significance of hyperexpression of epidermal growth factor receptors (EGFR and HER-2) in esophageal squamous cell carcinoma. Bull Exp Biol Med 148:241–245

    Article  PubMed  CAS  Google Scholar 

  4. Sano A, Sakurai S, Kato H et al (2009) Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma. Anticancer Res 29:3375–3380

    PubMed  CAS  Google Scholar 

  5. Kato H, Fukuchi M, Miyazaki T (2007) Surgical treatment for esophageal cancer. Current issues. Dig Surg 24:88–95

    Article  PubMed  Google Scholar 

  6. Bolli R, Dawn B, Xuan YT (2003) Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13:72–79

    Article  PubMed  CAS  Google Scholar 

  7. Booz GW, Day JN, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–1453

    Article  PubMed  CAS  Google Scholar 

  8. Gross ER, Hsu AK, Gross GJ (2006) The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT-3, Akt, and GSK-3ß. Am J Physiol Heart Circ Physiol 291:827–834

    Article  Google Scholar 

  9. Kandalam U, Clark MA (2010) Angiotensin II activates JAK2/STAT-3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul Pept 159:110–116

    Article  PubMed  CAS  Google Scholar 

  10. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630–1635

    Article  PubMed  CAS  Google Scholar 

  11. Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662

    Article  PubMed  CAS  Google Scholar 

  12. Calo V, Migliavacca M, Bazan V (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157–168

    Article  PubMed  CAS  Google Scholar 

  13. Bromberg JF (2001) Activation of STAT proteins and growth control. Bioessays 23:161–169

    Article  PubMed  CAS  Google Scholar 

  14. Williams JG (2000) STAT signaling in cell proliferation and in development. Curr Opin Genet Dev 10:503–507

    Article  PubMed  CAS  Google Scholar 

  15. Valdembri D, Serini G, Vacca A (2002) In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 16:225–227

    PubMed  CAS  Google Scholar 

  16. Tu Y, Zhong Y, Fu J et al (2011) Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 28:15–23

    Article  PubMed  CAS  Google Scholar 

  17. Tam L, McGlynn LM, Traynor P et al (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97:378–383

    Article  PubMed  CAS  Google Scholar 

  18. Hamilton S, Aaltonen L (2000) World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system. IARC, Lyon

    Google Scholar 

  19. Gao B, Shen XN, Kunos G (2001) Constitutive activation of JAK-STAT-3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 488:179–184

    Article  PubMed  CAS  Google Scholar 

  20. Song JI, Rubin Grandis J (2000) STAT signaling in head and neck cancer. Oncogene 19:2489–2495

    Article  PubMed  CAS  Google Scholar 

  21. Huang M, Page C, Reynolds RK (2000) Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79:67–73

    Article  PubMed  CAS  Google Scholar 

  22. Campbell CL, Jiang Z, Savarese DM (2001) Increased expression of the interleukin-11 receptor and evidence of Stat3 activation in prostate carcinoma. Am J Pathol 158:25–32

    Article  PubMed  CAS  Google Scholar 

  23. Berclaz G, Altermatt HJ, Rohrbach V (2001) EGFR dependent expression of Stat3 (but not STAT1) in breast cancer. Int J Oncol 19:1155–1160

    PubMed  CAS  Google Scholar 

  24. Page C, Huang M, Jin X (2000) Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int J Oncol 17:23–28

    PubMed  CAS  Google Scholar 

  25. Wei L, Kuo ML, Chen CA (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517–1527

    Article  PubMed  CAS  Google Scholar 

  26. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Exp Opin Ther Targets 5:409–422

    Article  Google Scholar 

  27. Turkson J, Tammy Bowman T, Garcia R et al (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545–2552

    PubMed  CAS  Google Scholar 

  28. Haura EB, Turkson J, Jove R (2005) Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2:315–324

    Article  PubMed  CAS  Google Scholar 

  29. Wang T, Niu G, Kortylewski M (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54

    Article  PubMed  Google Scholar 

  30. Niu G, Wright KL, Huang M (2002) Constitutive STAT3 activity up-regulates VEGF expression in tumor angiogenesis. Oncogene 21:2000–2008

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Surgery First Hospital of Huaian, Nanjing Medical University, Huaian, 223300, China

    Zhenbing You, Dafu Xu, Jian Ji & Wei Guo

  2. Department of Oncology First Hospital of Huaian, Nanjing Medical University, Huaian, 223300, China

    Weiguo Zhu & Jingdong He

Authors
  1. Zhenbing You
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dafu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weiguo Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jingdong He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Guo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

You, Z., Xu, D., Ji, J. et al. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clin Transl Oncol 14, 143–149 (2012). https://doi.org/10.1007/s12094-012-0774-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0774-6

Keywords

Search

Navigation